Global Suvorexant Tablet Market Strategic Research Report

Scope of the Report

The global Suvorexant Tablet market size is predicted to grow from US$ 357 million in 2025 to US$ 252 million in 2032; it is expected to grow at a CAGR of -5.0% from 2026 to 2032.

Suvorexant (brand name Belsomra) is a prescription medication used to treat insomnia, specifically helping adults fall asleep faster and stay asleep longer. It acts as a dual orexin receptor antagonist, blocking chemicals in the brain that promote wakefulness. It is taken orally, typically at a dose of 10-20 mg, 30 minutes before bed.

In 2025, the global production of Suvoresin tablets is 46.2 million tablets, with an average price of US$7.9 per tablet and an average gross profit margin of 81%.

Based on our research, the suvorexant market should be characterized as a highly focused single-molecule prescription drug market rather than a broad insomnia treatment segment. The appropriate scope is limited to finished oral tablets containing suvorexant and its associated supply chain, excluding other DORA drugs and traditional hypnotics. From a product perspective, suvorexant represents the first commercially successful dual orexin receptor antagonist, but its commercial performance remains heavily dependent on the BELSOMRA franchise rather than a multi-manufacturer expansion model.

From a supply structure standpoint, the finished dosage market remains highly concentrated, with Merck/MSD as the dominant player. Regional entities in Japan and Australia operate under the same corporate system, reinforcing the centralized nature of the finished drug segment. In contrast, the upstream API and intermediate supply chain is more diversified, with increasing participation from Chinese companies, particularly in custom synthesis, intermediate manufacturing, and potential generic pathways. This creates a dual-layer structure characterized by concentrated downstream commercialization and fragmented upstream supply.

From a demand perspective, suvorexant faces both structural support and competitive pressure. The DORA mechanism offers clinical advantages over traditional hypnotics, supporting its role in premium insomnia treatment. However, competing products such as lemborexant and daridorexant exert direct pressure on market share. As a result, while baseline demand is expected to remain stable, pricing dynamics and revenue growth are likely to weaken over time.

From a regulatory perspective, suvorexant operates under stricter frameworks compared to standard oral drugs, including controlled substance classification in the United States and additional prescription controls in other regions. These regulatory factors increase entry barriers for generics and suppliers, requiring not only chemical manufacturing capability but also compliance with regulatory, quality, and distribution requirements. Over time, the industry is expected to evolve from a single-originator model to a layered ecosystem involving originators, generic entrants, API suppliers, and specialized intermediate manufacturers.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Suvorexant Tablet market?

What factors are driving Suvorexant Tablet market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Suvorexant Tablet market opportunities vary by end market size?

How does Suvorexant Tablet break out by Type, by Application?

This report presents a comprehensive overview of the global Suvorexant Tablet market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 5 mg Tablets
• 10 mg Tablets
• 15 mg Tablets
• 20 mg Tablets
• Other

Segment by Regulatory Status

• Approved Originator Product
• Approved Generic Product
• Generic Under Filing

Segment by Application

• Sleep Onset Insomnia
• Sleep Maintenance Insomnia
• Mixed Insomnia
• Clinical Research
• Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Suvorexant Tablet market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Sleep Onset Insomnia, Sleep Maintenance Insomnia, Mixed Insomnia evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact